Bio
Tom leads the firm’s Emerging Companies and Venture Capital practice and is a member of the Investment Funds practice. With over 20 years of experience, he advises entrepreneurs, startups, venture capital funds, and private equity clients across a variety of industries, with an emphasis on technology, life sciences, and healthcare. Tom earned his B.A., cum laude, from Harvard University and his J.D., cum laude, from Harvard Law School.
Tom serves as outside general counsel to private companies at all stages of growth, advising on a wide range of matters, including the following.
- Formation: founder stock and initial capitalization, equity incentive plans, governing documents, stockholder agreements, invention assignment agreements, service provider arrangements, and LLC agreements
- Financings: SAFEs, convertible notes, preferred stock financings, secondary and exchange transactions, LLC interest issuances, founder loans, capital contributions, credit facilities, placement agent arrangements, offering document preparation, and securities law compliance
- Incentive Programs: equity incentive plans, stock options, restricted stock awards, and profits interests
- Corporate Governance: board and stockholder meetings, committee formation and oversight, fiduciary duty compliance, corporate approvals, protective provisions, and ratification processes
- Commercial Contracts: service provider arrangements, engagement letters, non-disclosure agreements, master service agreements, and other day-to-day commercial agreements
- Capitalization Management: day-to-day cap table management, pro forma and liquidity modeling, and securities transfers
- Liquidity Events: exit preparation, mergers, acquisitions, asset sales, stock sales, secondary transactions, dissolutions, and liquidations
Tom has extensive experience advising venture capital and private equity fund sponsors on fund formation, investments, and day-to-day operations and management. Representative matters include the following.
- Fund Formation: fund structuring, term sheet negotiation, general partner and management company organization, private placement memoranda, offering document preparation, SPV formation, regulatory compliance (including exemptions under the Investment Advisers Act of 1940, Investment Company Act of 1940, and ERISA), and securities law compliance
- Investments: deal structuring, term sheet negotiation, transaction document preparation and negotiation, investment incentives and penalties (including pay-to-play provisions), and ongoing portfolio company management (including exercise of approval rights, protective provisions, preemptive rights, and information rights)
- Incentive Programs: carried interest structuring, incentive plans, and regulatory exemption compliance (including key employee analysis)
- Fund Governance: governing document compliance, investment committee matters, LP advisory committee administration, LP reporting, and side letter management
- Liquidity Events: portfolio company exit document review and negotiation, and secondary sales
- Listed as “Raleigh Best Lawyers Biotechnology and Life Science Lawyer of the Year” (2025)
- Listed as “Raleigh Best Lawyers Venture Capital Lawyer of the Year” (2024)
- Listed among The Best Lawyers in America: Venture Capital Law (2018-2026), Biotechnology and Life Sciences Practice (2019-2026), Corporate Law (2021-2026), Mergers and Acquisitions Law (2021-2026)
- Listed among Business North Carolina Magazine Legal Elite: Business (2022, 2025)
- North Carolina State Bar
- American Bar Association
- Served as company counsel for $2 million Series Seed Preferred Stock financing of a digital security company
- Served as investor counsel for $10 million Series C Preferred Stock financing of digital healthcare company
- Served as fund counsel for the formation of a private equity fund with a target size of $100 million
- Served as investor counsel for $3 million Series A Preferred Stock financing of a fintech company
- Served as company counsel for $20 million Series A Preferred Stock financing of a life sciences company
- Served as fund counsel for the formation of a venture capital fund with a target size of $200 million
- Served as investor counsel for $5 million Series B Preferred Stock financing of a pharmaceutical company
- Served as investor counsel for $1 million Series Seed Preferred Stock financing of a digital healthcare company
- Served as company counsel for $6 million Convertible Promissory Note and Warrant financing of a biotechnology company
- Served as fund counsel for the formation of a special purpose investment vehicle with $30 million in committed capital
Recent posts from our emerging companies blog, Wyrick Ventures.